Latest news articles

Added 3 hours ago Drug news

FDA approves Avsola, infliximab biosimilar, for all indications of the reference product.- Amgen

Amgen has announced that the FDA has approved Avsola (infliximab-axxq) for all approved indications of the reference product, Remicade (infliximab):...

Added 1 month ago Drug news

FDA approval for Stelara to treat moderately to severely active ulcerative colitis.- Janssen Pharma

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the FDA approval of Stelara (ustekinumab) for the treatment of adult...

Added 1 month ago Congress news

UEGW 2019: STELARA® (USTEKINUMAB) DATA DEMONSTRATE LONG-TERM EFFICACY AND SAFETY RESULTS IN ADULTS

Two-year UNIFI data presented for the first time as a late breaking oral presentation at United European Gastroenterology Week (UEGW) congress

Search all news articles for Regional enteritis and ulcerative colitis
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Inflammatory Bowel Disease Knowledge Centre

Inflammatory Bowel Disease Knowledge Centre

The Inflammatory Bowel Disease (IBD) Knowledge Centre contains key information relating to the epidemiology and pathophysiology of Crohn’s disease and ulcerative colitis, highlighting prevalence, impact and unmet needs and the underlying inflammatory processes that drive IBD, considering some of the key inflammatory pathways.

Inflammatory bowel disease assessment tools

Inflammatory bowel disease assessment tools

'New IBD assessment tools at a glance' - an educational symposium sponsored by Sandoz.

Load more

Guidelines

Ulcerative colitis: management

This guideline covers the management of ulcerative colitis in children, young people and adults. It aims to help professionals to provide consistent high-quality care and it highlights the importance of advice and support...

Added 3 months ago

Crohn's disease: management

Crohn's disease is a chronic inflammatory disease that mainly affects the gastrointestinal tract. The disease may be progressive in some people, and a proportion may develop extra-intestinal manifestations.

Added 7 years ago

Guidelines for the investigation of chronic diarrhoea in adults: British Society of Gastroenterology, 3rd edition

Chronic diarrhoea is a common problem, hence clear guidance on investigations is required. This is an updated guideline from 2003 for the investigations of chronic diarrhoea...

Added 1 year ago

Search all guidelines for Regional enteritis and ulcerative colitis
 

Journal articles

Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis.

Background & Aims: Maintenance treatment with vedolizumab, a monoclonal antibody that inhibits the gut-selective α4β7 integrin, is administered intravenously. Some patients might prefer a subcutaneous formulation of...

Added 19 days ago

The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-Marketing Data.

Background and Aims: Vedolizumab is a gut-selective antibody to α4 β7 integrin, approved to treat moderate-to-severe ulcerative colitis and Crohn’s disease in adults.

Added 1 month ago

Mucosal Biomarker of Innate Immune Activation Predicts Response to Vedolizumab in Crohn's Disease.

Objective: Mucosal barrier dysfunction plays a crucial role in intestinal inflammation in Crohn’s disease (CD). Intestinal epithelial cell (IEC) death resulting from innate immune activation, termed pyroptosis, was recently...

Added 1 month ago

Search all journal articles for Regional enteritis and ulcerative colitis
 

Clinical trials

The Impact of Anti-TNF Exposure on Vedolizumab Effectiveness

Vedolizumab is a new medication being used for the treatment of Crohn's disease and Ulcerative colitis. It works by blocking specific white blood cells (alpha 4-beta7 lymphocytes) from migrating to areas of inflammation in...

Added 1 year ago

A Study to Assess Whether Etrolizumab is a Safe and Effective Treatment for Participants With Moderately to Severely Active Crohn's Disease (CD) (BERGAMOT)

This is a multicenter, Phase 3, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of etrolizumab compared with placebo during induction and maintenance treatment of moderate to severely active CD...

Added 1 month ago

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy

To determine the efficacy and safety of multiple doses of ABT-494 in subjects with moderately to severely active Crohn's Disease with a history of inadequate response to or intolerance to Immunomodulators or anti-Tumor Necrosis Factor...

Added 1 year ago

Search all clinical trials for Regional enteritis and ulcerative colitis
 
Allen Wellings

UEGW 2018 | Day 5 Highlights

A number of presentations and abstracts shared updates on the latest developments for new treatments and therapies, some of which are pioneering new modes of action. Here we look to the horizon, gaining insights into the latest data for novel treatments targeting Janus kinase (JAK) signalling, MAdCAM-1-mediated adhesion and the interleukin IL-23.